Coexpression and clinical significance of APE1 and P53 in peripheral T-cell lymphomas: report of 178 cases

谢家印; 王东; 牟江洪; 肖华亮; 李梦侠; 向德兵; 仲召阳; 王阁

您当前的位置：

首页 >

文章列表页 >

Coexpression and clinical significance of APE1 and P53 in peripheral T-cell lymphomas: report of 178 cases

更新时间：2026-01-09

- Coexpression and clinical significance of APE1 and P53 in peripheral T-cell lymphomas: report of 178 cases
- Journal of Army Medical University Vol. 31, Issue 6, Pages: 510-514(2009)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：
  CLC： R394.2;R730.23;R730.263
- Published：2009
- 稿件说明：
移动端阅览
谢家印,王东,牟江洪,肖华亮,李梦侠,向德兵,仲召阳,王阁.外周T细胞淋巴瘤APE1和P53蛋白联合表达的临床意义[J].陆军军医大学学报(原第三军医大学学报),2009,31(06):510-514.

　XIE Jia-yin,WANG Dong,MOU Jiang-hong,XIAO Hua-liang,LI Meng-xia,XIANG De-bing,ZHONG Zhao-yang,WANG Ge.Coexpression and clinical significance of APE1 and P53 in peripheral T-cell lymphomas: report of 178 cases[J].J Amry Med Univ (J Third Mil Med Univ),2009,31(06):510-514.
谢家印,王东,牟江洪,肖华亮,李梦侠,向德兵,仲召阳,王阁.外周T细胞淋巴瘤APE1和P53蛋白联合表达的临床意义[J].陆军军医大学学报(原第三军医大学学报),2009,31(06):510-514. DOI：

　XIE Jia-yin,WANG Dong,MOU Jiang-hong,XIAO Hua-liang,LI Meng-xia,XIANG De-bing,ZHONG Zhao-yang,WANG Ge.Coexpression and clinical significance of APE1 and P53 in peripheral T-cell lymphomas: report of 178 cases[J].J Amry Med Univ (J Third Mil Med Univ),2009,31(06):510-514. DOI：

摘要

目的研究外周T细胞淋巴瘤（peripheral T-cell lymphomas，PTCLs）APE1和P53蛋白联合表达与临床特征、化疗效果及预后的关系。方法免疫组化法检测178例PTCLs患者瘤细胞APE1和P53蛋白表达情况，采用单因素和多因素分析比较APE1和P53蛋白表达及联合表达与临床特征、预后的关系。结果 PTCLs患者APE1和P53蛋白表达阳性率分别为82.6%(147/178)和40.5%（72/178），其中血管免疫母T细胞淋巴瘤（ATL）和外周T细胞淋巴瘤-非特异型（PTCL-U）患者的APE1表达阳性率显著高于结外NK/T细胞淋巴瘤（NK/TL）、皮下脂膜炎样T细胞淋巴瘤（CTCL）和间变大T细胞淋巴瘤（ALCL）患者（P0.05）。具有APE1

/P53

共表达患者的临床分期以Ⅲ+Ⅳ为主，中、高危患者比例高；APE1

/P53

组与APE1

/P53

组患者化疗疗效显著低于APE1

/P53

组和APE1

/P53

组（P0.01）；APE1

/P53

组和APE1

/P53

组患者总生存率明显低于APE1

/P53

和APE1

/P53

2组（P0.01），APE1

/P53

组患者无病生存时间（DFS）明显低于其他3组（P0.01）；单因素生存分析显示APE1及P53呈阳性表达、APE1

/P53

和APE1

/P53

联合表达与患者预后不良有关(P0.05)，APE1

/P53

和APE1

/P53

联合表达均与3年生存率有关（P0.05，P0.01）；多因素生存分析显示APE1

/P53

共表达患者预后最差（P0.01）。结论 APE1、P53表达阳性，以及APE1

/P53

、APE1

/P53

联合表达的患者预后不良；APE1

/P53

共表达为PTCLs患者独立预后因素。

Abstract

Objective To study the relationship of the coexpression of APE1 and P53 with clinical related-parameters of the stages

international prognostic indexes

chemotherapeutic efficacy and prognosis in peripheral T-cell lymphomas (PTCLs). Methods Totally lymphoma specimens from 178 PTCLs patients were collected including 90 cases of peripheral T-cell lymphoma-unspecified (PTCL-U)

42 of extranodal NK/T cell lymphoma(NK/TL)

22 of anaplastic large T-cell lymphoma (ALCL)

20 of angioimmuno-blastic T-cell lymphoma (ATL)

and 4 of subcutaneous panniculitis-like T-cell lymphoma（CTCL）. Expressions of APE1 and P53 were detected with immunohistochemical method in these 178 specimens. The correlations of the expressions of APE1 and P53 alone or combined together with the clinical features as well as prognosis were statistically analyzed with univariate and multivariate analyses. Results The APE1 expression and the P53 expression were positive in 147(82.6%) and 72 of 178 cases (40.5%) respectively. The positive rate of APE1 in the patients with ATL and PTCL-U was significantly higher than that in the patients with NK/TL

CTCL and ALCL (P0.05). Most patients with the APE1

/P53

coexpression were belonged to stage Ⅲ and Ⅳ and intermediate or high risk condition. The response rates of the patients in APE1

/P53

group and APE1

/P53

group were very lower than those of the patients in APE1

P53

group and APE1

P53

group (P0.01)

meanwhile

the survival rates in APE1

/P53

group and PE1

/P53

group were significant lower than those in APE1

/P53

group and APE1

/P53

group(P0.01). The disease-free survival time in APE1

/P53

group was very lower than that in the other 3 groups

(P0.01). Univariate analysis showed that the positive expressions of APE1 or P53 and coexpression of APE1

/P53

and APE1

/P53

were significantly correlated with the poor prognosis all together (P0.05)

and the coexpressions of APE1

/P53

and APE1

/P53

were with 3-years survival rate respectively (P0.05 and P0.01). Multivariate analysis with the Cox regression models showed that the coexpression of APE1

/P53

was significantly associated with the poor prognosis(P0.01). Conclusion The respective expression of APE1

or P53

the coexpression of APE1

/P53

and APE1

/P53

are indicators of the poor prognosis in PTCLs patients; What’s more

the coexpression of APE1

/P53

may be also a independent prognosis factor for PTCLs.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

A novel estrogen receptor expression stratification (low/moderate/high) based on Chinese population provides more accurate prognosis prediction for HR⁺/HER2^- early breast cancer patients

Immunosuppressive microenvironment of TGIF1-overexpressing gastric cancers and its clinical significance

Impact of molecular heterogeneity of NPM1 mutations on prognosis of acute myeloid leukemia: a clinical report of 86 cases

Association of 5-factor modified frailty index and controlling nutritional status score with overall survival in patients with unresectable hepatocellular carcinoma undergoing interventional therapy

Construction and validation of prediction model for cervical cancer recurrence based on systemic inflammation response index and clinicopathological parameters

Related Author

WANG Chengfang

ZHOU Yuqin

ZHANG Yanling

QI Xiaowei

ZHANG Yi

TONG Huyun

CHEN Xu

ZHANG Wenjie

Related Institution

Department of Breast and Thyroid Surgery， First Affiliated Hospital， Army Medical University （Third Military Medical University）

Department of Gastroenterology， Chongqing Hechuan District People’s Hospital

School of Medicine， Chongqing University

Chongqing Key Laboratory of Precision Prevention and Treatment for Digestive System Tumors， Department of Gastroenterology， Army Medical Center of PLA/Daping Hospital of Third Military Medical University

Department of Hematology, the First Hospital of Lanzhou University

⁰